Spark Therapeutics Inc. (ONCE) CEO Sells $626,800.00 in Stock
Spark Therapeutics Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 10,000 shares of the business’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $62.68, for a total transaction of $626,800.00. Following the sale, the chief executive officer now owns 240,000 shares in the company, valued at approximately $15,043,200. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 62.21 on Friday. The stock’s market cap is $1.90 billion. The firm has a 50-day moving average price of $59.11 and a 200-day moving average price of $47.56. Spark Therapeutics Inc. has a 12 month low of $21.20 and a 12 month high of $66.00.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.97) by $0.07. The firm had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.17 million. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.60) EPS. Equities research analysts expect that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current fiscal year.
A number of analysts have recently commented on the stock. Zacks Investment Research cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 16th. Wedbush reiterated an “underperform” rating and issued a $29.00 price target (up previously from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $94.00 price target on shares of Spark Therapeutics in a research note on Thursday, August 11th. Jefferies Group reiterated a “hold” rating on shares of Spark Therapeutics in a research note on Friday, August 5th. Finally, Stifel Nicolaus began coverage on shares of Spark Therapeutics in a research note on Friday, September 2nd. They issued a “buy” rating and a $73.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Spark Therapeutics currently has an average rating of “Hold” and an average target price of $62.27.
Several institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas raised its position in shares of Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock valued at $124,000 after buying an additional 299 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Spark Therapeutics during the second quarter valued at approximately $124,000. Legal & General Group Plc raised its position in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock valued at $138,000 after buying an additional 1,394 shares in the last quarter. BlackRock Group LTD raised its position in shares of Spark Therapeutics by 92.6% in the first quarter. BlackRock Group LTD now owns 4,843 shares of the company’s stock valued at $143,000 after buying an additional 2,328 shares in the last quarter. Finally, AMG National Trust Bank purchased a new position in shares of Spark Therapeutics during the second quarter valued at approximately $256,000. Hedge funds and other institutional investors own 78.79% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.